CDSCO: how India regulates drugs, medical devices and cosmetics
The Central Drugs Standard Control Organization (CDSCO) is India's central regulator for drugs, medical devices and cosmetics under the Drugs and Cosmetics Act, 1940. The Drugs Controller General (India), or DCGI, heads it. CDSCO decides device imports, Class C and D manufacture, new drugs, trials and cosmetic imports; state drugs controllers license Class A and B device making and sale.
Published and updated

Share your requirement with our desk. We will respond with a clear scope and a practical path forward.
Talk to our desk about CDSCOWhere do CDSCO's rules stand on November 8, 2026?
On November 8, 2026, CDSCO's rules rest on the Drugs and Cosmetics Act, 1940 and its rules. In 2026 European Union approvals joined the waiver for new devices, imported drugs began to need a year of shelf life, and CDSCO started rejecting long-pending applications left unanswered after three reminders.
As of November 8, 2026
We read 56 official texts on November 8, 2026. They include the Act, the rules, the 2024 to 2026 Gazette notifications, CDSCO's FAQs and notices, and a Central Board of Indirect Taxes and Customs (CBIC) circular. CDSCO's compilations lag, so we cite each later amendment.
Changes since September 2025:
- September 15, 2025: CDSCO says a later importer of an approved device has had its own portal route since September 11 (circular (MED-13011/16/2025-eoffice, 2025-09-15), opens in a new tab).
- October 7, 2025: CDSCO asks Customs to send bills of entry on ICEGATE, Customs' online system, to its port offices (letter (IMP-12018(19)/13/2025-eoffice, 2025-10-07), opens in a new tab).
- October 31, 2025: CDSCO lists the Class A non-sterile, non-measuring devices (list, opens in a new tab).
- November 2025: CDSCO asks buyers to require an Indian device licence (circular (MED-13/87/2025-eoffice, 2025-11-17), opens in a new tab).
- December 4, 2025: CDSCO says a risk classification module has been open on the device portal since November 27, 2025 (circular (MED-16035/14/2025-eoffice, 2025-12-04), opens in a new tab).
- January 16, 2026: long-pending applications on SUGAM, CDSCO's online portal, are rejected after three unanswered reminders (notice (IT-11011(11)/1/2026, 2026-01-16), opens in a new tab).
- January 20, 2026: permission to make new drugs for trials or tests gets a forty-five working day limit, in force 45 days after publication (G.S.R. 46(E), opens in a new tab).
- January 30, 2026: draft guidance for importers of in vitro diagnostic (IVD) devices (draft, opens in a new tab).
- July 21, 2026: final guidance on medical device software (guidance, opens in a new tab).
- July 30, 2026: applicants under the Drugs Rules who file misleading, fake or fabricated documents may face debarment (G.S.R. 706(E), opens in a new tab).
- August 14, 2026: labels must name an outsourced sterilization site's licence from mid-February 2027 (G.S.R. 743(E), opens in a new tab), and European Union approvals count for new devices (G.S.R. 744(E), opens in a new tab).
- September 3, 2026: Customs checks CDSCO's checklists before clearing drugs, devices and cosmetics on "PGA facilitated" bills of entry (Circular No. 40/2026-Customs, opens in a new tab).
- October 16, 2026: imported drugs need one year of shelf life left, from the Gazette of October 28 (G.S.R. 951(E), opens in a new tab).
- October 28, 2026: three drafts on drug import points, batch release and licence suspension (G.S.R. 954(E), opens in a new tab, 955(E), opens in a new tab, 956(E), opens in a new tab).
| Guide | What it answers |
|---|---|
| Medical device registration in India | Classes, licences and the Class A route |
| Medical device import licence | Forms MD-14 and MD-15 |
| The Indian authorized agent | What foreign makers need |
| Medical device manufacturing licence | Forms MD-5 and MD-9 |
| Medical device labeling | Labels, and what you report after approval |
| Drug import licence | Form 41 registration and Form 10 |
| Clinical trial approval | Forms CT-04 and CT-06, and new drug permission |
| Cosmetics registration | Importing under COS-1 and COS-2 |
What is CDSCO, and what do the state drugs controllers decide?
CDSCO is the central regulator under the Drugs and Cosmetics Act, 1940. Its head, the DCGI, licenses devices centrally: imports of every class, Class C and D manufacture, clinical investigations and new IVDs. Each state's drugs controller licenses Class A and B device makers and cosmetic factories, and registers device sellers. CDSCO registers imported cosmetics.
| Activity | Authority | Form | Rule |
|---|---|---|---|
| Import any class of device | CDSCO | MD-14 for an MD-15 licence | MDR rules 8(1), 34 and 36, opens in a new tab |
| Make Class A or B devices | The state's drugs controller | MD-3 for an MD-5 licence | MDR rules 8(2) and 20 |
| Make Class C or D devices | CDSCO | MD-7 for an MD-9 licence | MDR rules 21 and 25 |
| Sell devices | The state's drugs controller | MD-41 for an MD-42 registration | MDR rule 87A |
| Register imported cosmetics | CDSCO | COS-1 for a COS-2 certificate | Cosmetics Rules, 2020, rules 4(1), 12 and 13, opens in a new tab |
| License cosmetic factories and oversee cosmetics on sale | The state's licensing authority | A state licence to manufacture | Cosmetics Rules, 2020, rule 4(2) |
| Register and license drug imports | A licensing authority the central government appoints | Form 40 for a Form 41 certificate; Form 8 for a Form 10 licence | Drugs Rules, 1945, rules 21 to 24A, opens in a new tab |
| Approve clinical trials and new drugs | CDSCO, the DCGI | CT-04 for a CT-06 trial permission | New Drugs and Clinical Trials Rules, 2019, rules 21 and 22, opens in a new tab |
Since 2020 every medical device is regulated under the Medical Devices Rules, 2017, which override the older Drugs Rules where the two conflict (rule 96; device FAQ, question 1, opens in a new tab). CDSCO runs a public relations cell in New Delhi for device startups, importers and makers (question 7).
Is your product a drug, a medical device or a cosmetic?
The Drugs and Cosmetics Act, 1940 decides it. A cosmetic is anything rubbed, poured, sprinkled or sprayed on the body to clean, beautify, add attractiveness or change appearance. A device counts as a drug once the government notifies it. A product given as an injection isn't a cosmetic, CDSCO said in May 2026.
- The definitions are in section 3 of the Act, opens in a new tab. No cosmetic may be used as an injection or for treatment (notice of May 18, 2026, opens in a new tab).
- A massager for soothing or wellness isn't regulated; one meant for a therapeutic purpose is a device (device FAQ, question 51, opens in a new tab).
- Only surgical, medical examination and other medical gloves are devices (addendum 02, question 32, opens in a new tab).
- Radiopharmaceuticals aren't devices; the Drugs Rules, 1945 license them (addendum 03, question 14, opens in a new tab).
- A microscope in a food plant, or other non-medical lab equipment, isn't a device (addendum 03, question 18).
Software that meets the device definition is a device, standalone software included: see medical device registration in India.
What are India's medical device risk classes?
Medical devices fall into four risk classes under rule 4 of the Medical Devices Rules, 2017: A (low), B (low moderate), C (moderate high) and D (high). In vitro diagnostic devices use the same four classes under their own parameters. Only CDSCO's Central Licensing Authority classifies a device; a maker can't set its own class.
| Class | Risk | Manufacturing licence from |
|---|---|---|
| Class A | Low | The state; registration only, if non-sterile and non-measuring |
| Class B | Low moderate | The state |
| Class C | Moderate high | CDSCO |
| Class D | High | CDSCO |
CDSCO classifies by intended use (rule 4(3), opens in a new tab) and, where another country classes a device differently, may apply the higher class (device FAQ, question 93, opens in a new tab); see medical device registration in India.
Which approval does a medical device need?
A medical device needs the approval that matches what you do with it. Class A non-sterile, non-measuring devices are registered on CDSCO's portal. Every other import needs an MD-15 licence, making a device needs a state or central manufacturing licence by class, and a shop selling only devices needs an MD-42 registration.
| What you do | Application | Approval | Rule |
|---|---|---|---|
| Make or import a Class A non-sterile, non-measuring device | Details on the online portal | A registration number | Rules 19G to 19K, opens in a new tab |
| Import any other device | Form MD-14 | Licence in Form MD-15 | Rules 34 and 36 |
| Make Class A or B devices | Form MD-3 (MD-4 for a loan licence) | Form MD-5 or MD-6 | Rule 20 |
| Make Class C or D devices | Form MD-7 (MD-8 for a loan licence) | Form MD-9 or MD-10 | Rules 21 and 25 |
| Sell devices only | Form MD-41 | Registration in Form MD-42 | Rule 87A |
| Make devices to test, demonstrate or train | Form MD-12 | Test licence in Form MD-13, for three years | Rule 31 |
| Import devices to test, demonstrate or train | Form MD-16 | Test licence in Form MD-17, for three years | Rules 40 and 41 |
What does a new device with no predicate need?
A new medical device with no predicate needs a clinical investigation permitted in Form MD-23, then MD-27 permission before any import or manufacturing licence. The authority may waive the investigation for a device approved and marketed for at least two years in the UK, the US, Australia, Canada, Japan or, since August 2026, the EU.
- A licensed device claimed for a new use, population or material, or with a major design change, is investigational too (device FAQ, question 112, opens in a new tab).
- The applicant files Form MD-26 after the investigation, and CDSCO decides within 120 days, extendable by thirty (rule 63, opens in a new tab).
- European Union countries joined the waiver under G.S.R. 744(E), paragraph 5, opens in a new tab, of August 14, 2026, in force from its Gazette of August 19.
- Once approved and sold in India, it becomes a predicate for later applicants (question 116).
How do you import medical devices into India?
To import a medical device, an authorized agent in India files Form MD-14 online, and CDSCO decides on the import licence, Form MD-15, within nine months under rule 36(1). Every class needs it, except Class A non-sterile, non-measuring devices. The licence has no end date while a retention fee is paid every five years.
- 1. Appoint an Indian authorized agent by power of attorney.
- 2. Get a free sale certificate; one from Australia, Canada, Japan, the European Union, the UK or the US needs no clinical investigation (rule 36(3), opens in a new tab).
- 3. From any other country, Class C and D need a clinical investigation in India (rule 36(4)). Class A and B need published data or an investigation abroad, plus a home-country free sale certificate (rule 36(5)).
- 4. File Form MD-14 on the portal, through the agent, and answer CDSCO's questions until it decides on Form MD-15.
The medical device import licence guide covers the dossier, inspection and later importers.
What does a foreign maker need in India?
A foreign device maker sells in India through an Indian authorized agent, appointed by power of attorney, who holds the MD-15 import licence. Changing that agent needs a fresh import licence. For cosmetics, the foreign maker may apply itself or through its agent, an importer or an Indian subsidiary it authorizes.
Sources: Medical Devices Rules, rule 3(f), opens in a new tab, CDSCO's device FAQ, question 104, opens in a new tab and Cosmetics Rules, rule 12(2), opens in a new tab. The Indian authorized agent covers what the agent holds and signs.
How is making medical devices in India licensed?
Making medical devices in India needs a licence by class. The state licenses Class A and B makers in Form MD-5, after a Notified Body audit for Class B. CDSCO licenses Class C and D makers in Form MD-9. The licences have no end date while a retention fee is paid.
- A Class A licence needs no audit first; a Notified Body audits the site within 120 days after the grant (rule 20(4), opens in a new tab).
- For Class B, the state, not the maker, assigns the Notified Body (device FAQ, question 83, opens in a new tab).
- A missed retention fee may be paid late for 180 days. After that the licence is deemed canceled (rule 29).
- A June 2026 draft, not yet law, proposes shorter timelines for Class B, C and D licences (G.S.R. 515(E), opens in a new tab).
The medical device manufacturing licence guide covers the quality system, staff and audits.
What do device labels and post-market rules require?
Chapter VI of the Medical Devices Rules, 2017 sets what a device label shows: the name, the maker and factory address, the quantity, dates, batch number, sterility and warnings. After approval, an importer gets a major change approved, or deemed approved after sixty days, and reports a minor change within thirty days.
See rule 44, opens in a new tab for labels and rule 38(1)(v) to (vii) for changes. Medical device labeling in India covers stickers, shelf life, recalls and change lists.
How do devices reach hospitals and buyers?
Devices reach buyers through sellers the state has registered. A shop or distributor dealing only in devices needs a Form MD-42 registration from the state; a wholesale drug licence also covers devices. CDSCO asked buyers, hospitals included, in November 2025 to require a CDSCO or state licence when they buy devices.
- The seller applies on Form MD-41 (rule 87A, opens in a new tab): see medical device registration in India.
- Any other certificate a buyer wants, such as a US FDA approval or a CE mark, is over and above that licence (November 2025 circular, opens in a new tab).
- The licensing authority may issue free sale and market standing certificates for tenders or export; a market standing certificate lasts a year (device FAQ, questions 41 to 43, opens in a new tab).
How do you import drugs into India?
Importing a drug for sale takes two approvals under the Drugs Rules, 1945: a registration certificate in Form 41 for the foreign factory and its drugs, and an import licence in Form 10. Each lasts three years. Since October 2026, an imported drug needs a year of shelf life left.
- 1. Apply on Form 40 for the registration certificate, through the maker's authorized agent in India, or as the maker with an Indian wholesale licence (rule 24A(1), opens in a new tab).
- 2. Apply on Form 8 for the import licence, with the Form 41 certificate and the maker's undertaking in Form 9 (rule 24).
- 3. Ship drugs with a year of shelf life left, or 60% for biologicals and radiopharmaceuticals (G.S.R. 951(E), opens in a new tab).
- 4. Apply for fresh ones before the three years end (rules 28 and 28A).
The drug import licence guide covers Schedule X drugs, test licences and renewal.
How are new drugs and clinical trials approved?
A clinical trial of a new drug needs permission from the Central Licensing Authority: you apply on Form CT-04 and receive Form CT-06. The authority decides within ninety working days, or the permission is deemed granted. Importing a new drug for sale needs permission on Form CT-18, granted in Form CT-19 or CT-20.
A local trial may be waived for a drug approved and marketed in countries named under rule 101, with no major unexpected serious adverse events (New Drugs and Clinical Trials Rules, 2019, rule 75(7), opens in a new tab).
The clinical trial approval guide covers ethics committees, bioavailability and bioequivalence (BA/BE) studies, and the 2026 routes.
How are imported cosmetics registered in India?
No cosmetic may be imported into India unless CDSCO has registered it. The maker, its authorized agent, the importer or an Indian subsidiary applies online on Form COS-1, and CDSCO grants a COS-2 certificate, or rejects it, within six months. COS-2 has no end date while a retention fee is paid.
See rules 12 to 14 of the Cosmetics Rules, 2020, opens in a new tab. No cosmetic tested on animals after November 12, 2014 may be imported (rule 18(4)). The cosmetics registration guide covers labels, COS-4A numbers and the 2026 cancellations.
How do CDSCO applications work, and when are they rejected?
Device applications go online through CDSCO's medical devices portal or the National Single Window System (NSWS). Drug, trial and cosmetic applications go on CDSCO's SUGAM portal. Since January 2026, a long-pending SUGAM application left waiting on the applicant gets three reminders thirty days apart, then a fourth notice rejects it and forfeits the fee.
- Device fees aren't refunded (device FAQ, question 14, opens in a new tab). An incomplete application to make Class C or D devices is rejected, but fixable gaps restart its scrutiny clock (rule 21(7), opens in a new tab).
- The January 16, 2026 notice, opens in a new tab covered drug, cosmetic and device files pending since 2016 or 2018; the May 4, 2026 notice, opens in a new tab added trial, BA/BE, ethics committee and veterinary files.
- A device application resting on fake or fabricated documents is rejected after a hearing, and the applicant may face debarment (rules 92 and 93).
- A retention application filed on time with the fee keeps a device licence deemed valid while it is processed (device FAQ, question 141).
CDSCO's cosmetics FAQ, opens in a new tab still says there is no time limit to answer on a cosmetics application; the 2026 notices are the later word.
What do CDSCO and Customs check at the port?
At the port, CDSCO's port office gives a no objection and Customs clears the goods. Drugs, devices and cosmetics enter India only through the places listed in rule 43A of the Drugs Rules, 1945. Since September 2026, Customs officers check CDSCO's checklists on "PGA facilitated" bills of entry before release.
- Rule 43A applies to cosmetics too (Cosmetics Rules, rule 22, opens in a new tab). Cochin and Thiruvananthapuram airports joined it in May 2024 (G.S.R. 293(E), opens in a new tab) and Navi Mumbai in July 2026 (G.S.R. 561(E), opens in a new tab).
- CDSCO's 2021 port notice, opens in a new tab sets two to three hours for a no objection on documents alone, 24 to 48 hours with a physical check, and 48 to 72 hours when a lab tests samples. That's CDSCO's own figure, not a promise for any shipment.
- Shelf life left on import: devices 40%, 50% or 60%, by total shelf life (Medical Devices Rules, rule 47, opens in a new tab); drugs one year (G.S.R. 951(E), opens in a new tab); cosmetics a use-before date over six months away (Cosmetics Rules, rule 18(2), opens in a new tab).
Duty and the bill of entry are on customs in India, and import restrictions on India import policy.
What enforcement and quality rules apply?
The Drugs and Cosmetics Act bars importing misbranded, adulterated or spurious drugs and misbranded or spurious cosmetics, and lets the central government ban a drug or cosmetic in the public interest. It banned 16 fixed dose combinations in June 2026. Some offenses may be compounded under section 32B.
- Bans: sections 10, 10A and 26A of the Act, opens in a new tab; the June 2026 combinations (S.O. 3068(E) to 3083(E), opens in a new tab).
- The compounding rules were notified on April 24, 2025 (notice (DCG(I)/Legal/Misc.-160/2025-DC, 2026-01-01), opens in a new tab); it's at the authority's discretion (FAQ, question 20, opens in a new tab).
- The Jan Vishwas (Amendment of Provisions) Act, 2026 changes to the Act take effect on June 30, 2027 (S.O. 3286(E), opens in a new tab).
- Drug makers must test every batch of raw material and finished product, CDSCO told states in October 2026 (letter (CDSCO asks states to enforce batch testing of drug raw materials, 2026-10-27), opens in a new tab).
- Two drafts of October 28, 2026 would require an authorized person to release each drug batch (G.S.R. 955(E), opens in a new tab) and suspend a manufacturing licence on a not of standard quality report until corrective action (G.S.R. 956(E), opens in a new tab). Both are drafts.
- CDSCO may order a whole device batch withdrawn or recalled, from hospitals too (Medical Devices Rules, rule 38(2), opens in a new tab).
What time limits do CDSCO's rules set?
CDSCO's rules set their own time limits. An MD-15 import licence is decided within nine months, a COS-2 cosmetic registration within six, and trial permission within ninety working days. These are the government's own limits, counted as each rule counts them, not a promise of a decision by a date.
| What is decided | Limit | Counted from | Rule |
|---|---|---|---|
| MD-15 device import licence | 9 months | Application | Medical Devices Rules, rule 36(1), opens in a new tab |
| IVD import and test licences | Draft only: 270 days for MD-14, 30 days for MD-16 | Application | Draft IVD guidance, section 11, opens in a new tab |
| Class C or D manufacturing licence | Scrutiny 45 days; inspection 60 days; decision 45 days | The application; then the inspection report | Rules 21(4), 23(1), 25(1) |
| Class B manufacturing licence | Audit 90 days; report 30 days; decision 20 days | The application; the audit; its report | Rule 20(6) |
| Device test licence, MD-13 or MD-17 | 30 days | Application | Rules 31(3) and 41(1) |
| Device with no predicate, MD-27 | 120 days, plus up to 30 | Application | Rule 63(2) |
| Personal use permit for a device | 7 days | Application | Rule 43(3) |
| Appeal against most device refusals | 45 days to file | The order | Rules 20(7), 25(2), 30(2), 36(2) |
| Form 41 drug registration certificate | 9 months, plus up to 3 | A complete application | Drugs Rules, rule 27A(1), opens in a new tab |
| COS-2 registration or COS-4A number | 6 months | Application | Cosmetics Rules, rules 13(1), 17(2), opens in a new tab |
| Clinical trial permission, CT-06 | 90 working days; 30 for a drug discovered, or researched and made, in India | Application | NDCT Rules, rules 22(2) and 23, opens in a new tab |
| New drug import permission | 90 working days | The CT-18 application | NDCT Rules, rule 76(1) |
| Port office no objection | 2 to 3 hours on documents; 24 to 48 with a physical check; 48 to 72 with lab testing | Not stated | CDSCO notice of September 10, 2021, opens in a new tab |
Which CDSCO dates are coming up?
The next CDSCO date is mid-February 2027, when device labels must show the licence number of an outsourced sterilization site. The Jan Vishwas Act, 2026 changes to the Drugs and Cosmetics Act start on June 30, 2027, and Schedule H2 widens on July 1, 2027 and July 1, 2028.
| Date | What | Source |
|---|---|---|
| From mid-February 2027 | Labels show an outsourced sterilization site's licence number | Worked out: six months from G.S.R. 743(E), opens in a new tab of August 14, 2026 |
| June 30, 2027 | Jan Vishwas Act, 2026 changes to the Drugs and Cosmetics Act start | S.O. 3286(E), opens in a new tab |
| July 1, 2027 | Schedule H2 covers vaccines, narcotic and psychotropic drugs and anticancer drugs | G.S.R. 506(E), opens in a new tab |
| July 1, 2028 | Schedule H2 covers all antimicrobials | G.S.R. 506(E), opens in a new tab |
Drafts not yet final: G.S.R. 515(E), opens in a new tab (device licence timelines), 509(E), opens in a new tab (drug test licences), 790(E), opens in a new tab (BA/BE studies) and 954(E), opens in a new tab, 955(E), opens in a new tab and 956(E), opens in a new tab of October 28, 2026.
What do pages online get wrong about CDSCO's rules?
Pages online often repeat CDSCO rules that changed or never existed: an MD-15 licence that expires after five years, Class A registration called voluntary, a trial approval time halved in 2026, and 60% shelf life for every imported drug. The table sets 13 such claims beside what the official documents say.
| What some pages say | What the documents say | Rule |
|---|---|---|
| An MD-15 import licence is valid for five years | No end date while the retention fee is paid every five years | MDR rule 37, opens in a new tab |
| A COS-2 cosmetic registration is valid for three or five years | No end date while the retention fee is paid | Cosmetics Rules, rule 14(1), opens in a new tab |
| Registering a Class A non-sterile, non-measuring device is voluntary | Mandatory and free; the portal issues the number | MDR rules 19G to 19K |
| MD-14 is the licence for Class A and B devices and MD-15 for Class C and D | MD-14 is the application and MD-15 the licence, for every class | MDR rules 34(1), 36(1) |
| CDSCO grants manufacturing licences for Class A and B devices | The state licenses Class A and B; CDSCO licenses C and D | MDR rules 8, 20, 21 |
| An import licence officially takes four to six months | An outer limit of nine months; no rule sets four to six | MDR rule 36(1) |
| The January 2026 amendment halved the time to approve a clinical trial | Trial permission still has ninety working days | NDCT rule 22(2), opens in a new tab; G.S.R. 46(E), opens in a new tab |
| Only five countries' approvals count for a device with no predicate | European Union approvals count too, since August 2026 | G.S.R. 744(E), opens in a new tab |
| Imported drugs need 60% of their shelf life left | One year since October 2026; 60% for biologicals | G.S.R. 951(E), opens in a new tab |
| Changing your Indian distributor only needs a letter to CDSCO | A new Indian agent needs a fresh import licence | Device FAQ, question 104, opens in a new tab |
| Imported cosmetics are registered on Form 42 and Form 43 | COS-1 and COS-2, since the Cosmetics Rules, 2020 | Cosmetics Rules, rules 12(2), 13(1) |
| Only notified devices need a licence; the rest just register | All devices need a licence, except Class A non-sterile, non-measuring ones | Device FAQ, question 2 |
| A device licence lets you import through any port | Only through ports notified under the Drugs Rules, 1945 | Device FAQ, question 106 |
Where do BIS, DGFT, Customs, MoEFCC and NPPA come in?
Other agencies' rules sit beside CDSCO's. A device must meet the Bureau of Indian Standards (BIS) standard where one exists, and cosmetics on the Ninth Schedule, hair dyes included, must meet theirs. Import policy, customs duty, e-waste rules and drug prices belong to other bodies.
- Standards: without a BIS standard, a device meets an international (ISO or IEC) standard or a pharmacopoeia (rule 7, opens in a new tab). Hair dyes: CDSCO's June 2026 circular, opens in a new tab, BIS licence in India and quality control orders.
- Import policy (the Directorate General of Foreign Trade, DGFT): India import policy. Duty: customs in India.
- E-waste, battery and used equipment rules: Ministry of Environment, Forest and Climate Change (MoEFCC) rules for companies.
- Drug prices: National Pharmaceutical Pricing Authority (NPPA) notices. IndusDesk shows no prices.
How IndusDesk helps with CDSCO
Share your requirement with our desk. We will respond with a clear scope and a practical path forward.
CDSCO and the states decide, so we never promise a licence, a registration or a date.
We aren't anyone's authorized agent or importer, and we never appear before an appellate authority or a court.
Frequently asked questions
What is the difference between CDSCO and the DCGI?
CDSCO is the organization; the Drugs Controller General (India), the DCGI, heads it. The DCGI is the Central Licensing Authority under the device rules and the trial rules.
Do I go to CDSCO or the state drugs controller?
It depends on the activity. Go to CDSCO for device imports, Class C and D manufacture, new drugs, trials and cosmetic imports, and to the state for Class A and B manufacture and device sales.
Can a consultant check my application status with CDSCO?
No. CDSCO says only an authorized person of the company may ask about a device application's status (device FAQ, question 11). A consultant prepares the papers; the company asks.
What happens if I don't answer CDSCO's questions on my application?
On a long-pending SUGAM application, CDSCO sends three reminders, thirty days apart, then a fourth notice rejects the application and the fee is forfeited. Its notice of January 16, 2026 set this out.
Which portal do I use for a CDSCO application?
Devices go through CDSCO's medical devices portal or the NSWS. Drugs, clinical trials and cosmetics go through SUGAM.
Can I appeal a CDSCO refusal?
For devices, yes: most refusals and cancellations under the Medical Devices Rules may be appealed to the State or Central Government within 45 days. A debarment for fake documents carries an appeal within thirty days.
Sources
- MED-13011/16/2025-eoffice: Separate provision for subsequent importer in the Online System for Medical Devices (CDSCO, September 15, 2025), opens in a new tab (PDF, 477 KB)
- IMP-12018(19)/13/2025-eoffice: Mapping of ICEGATE with CDSCO-notified ports (letter to the National Customs Targeting Centre) (CDSCO, October 7, 2025), opens in a new tab (PDF, 2.3 MB)
- F. No. MED-16014(12)/1/2024-eoffice-Part(2): Risk based classification list of Class A (non-sterile and non-measuring) medical devices (CDSCO, October 31, 2025), opens in a new tab (PDF, 1.0 MB)
- MED-13/87/2025-eoffice: Requirement of a licence issued by CDSCO or State Licensing Authorities in procurement of medical devices (CDSCO, November 2025), opens in a new tab (PDF, 467 KB)
- MED-16035/14/2025-eoffice: New provision for risk classification of medical devices on the CDSCO Online System for Medical Devices (CDSCO, December 4, 2025), opens in a new tab (PDF, 251 KB)
- IT-11011(11)/1/2026: Disposal or rejection of long-pending applications on the SUGAM portal awaiting a reply (CDSCO, January 16, 2026), opens in a new tab (PDF, 96 KB)
- G.S.R. 46(E): New Drugs and Clinical Trials (Amendment) Rules, 2026: prior intimation and 45 working days for test licences (Ministry of Health and Family Welfare, January 20, 2026), opens in a new tab (PDF, 733 KB)
- CDSCO/IVD/GD/DRAFT/IMP/01/2026: Draft guidance for import of in-vitro diagnostic medical devices (for comments) (CDSCO, January 30, 2026), opens in a new tab (PDF, 2.1 MB)
- CDSCO/MD/GD/MDSW/01/2026: Guidance Document on Medical Device Software under MDR-2017 (CDSCO, July 21, 2026), opens in a new tab (PDF, 1.6 MB)
- G.S.R. 706(E): Drugs (Eleventh Amendment) Rules, 2026: debarment for misleading, fake or fabricated documents (Ministry of Health and Family Welfare, July 30, 2026), opens in a new tab (PDF, 759 KB)
- G.S.R. 743(E): Medical Devices (Second Amendment) Rules, 2026: sterilization site licence number on labels and the Ninth Schedule (Ministry of Health and Family Welfare, August 14, 2026), opens in a new tab (PDF, 799 KB)
- G.S.R. 744(E): Medical Devices (Third Amendment) Rules, 2026: European Union countries in rule 63, and QMS for Class A non-sterile, non-measuring devices (Ministry of Health and Family Welfare, August 14, 2026), opens in a new tab (PDF, 740 KB)
- Circular No. 40/2026-Customs: Checklists for cosmetics, drugs and medical devices to be verified before out-of-charge (CBIC, September 3, 2026), opens in a new tab (PDF, 3.3 MB)
- G.S.R. 951(E): Drugs (Thirteenth Amendment) Rules, 2026: one year of residual shelf life for imported drugs (Ministry of Health and Family Welfare, October 16, 2026), opens in a new tab (PDF, 572 KB)
- G.S.R. 954(E): Draft amendment of rule 43A of the Drugs Rules, 1945: more inland container depots, an SEZ and an airport (Ministry of Health and Family Welfare, October 28, 2026), opens in a new tab (PDF, 616 KB)
- G.S.R. 955(E): Draft amendment of the Drugs Rules, 1945: an authorized person for batch release (Ministry of Health and Family Welfare, October 28, 2026), opens in a new tab (PDF, 706 KB)
- G.S.R. 956(E): Draft amendment of the Drugs Rules, 1945: suspension of product permission on a not of standard quality report until CAPA (Ministry of Health and Family Welfare, October 28, 2026), opens in a new tab (PDF, 653 KB)
- G.S.R. 78(E): The Medical Devices Rules, 2017 (CDSCO compilation, as amended by G.S.R. 777(E) of October 14, 2022) (Ministry of Health and Family Welfare), opens in a new tab (PDF, 1.6 MB)
- G.S.R. 763(E): The Cosmetics Rules, 2020 (Ministry of Health and Family Welfare, December 15, 2020), opens in a new tab (PDF, 773 KB)
- The Drugs Rules, 1945 (CDSCO compilation, as amended by G.S.R. 360(E) of July 1, 2024) (Ministry of Health and Family Welfare), opens in a new tab (PDF, 7.1 MB)
- G.S.R. 227(E): The New Drugs and Clinical Trials Rules, 2019 (CDSCO compilation, as amended by G.S.R. 778(E) of October 14, 2022) (Ministry of Health and Family Welfare), opens in a new tab (PDF, 1.7 MB)
- CDSCO/FAQ/MD/01/2024: Medical Devices Frequently Asked Questions (CDSCO, 2024), opens in a new tab (PDF, 507 KB)
- Act No. 23 of 1940: The Drugs and Cosmetics Act, 1940 (Parliament of India, April 10, 1940), opens in a new tab (PDF, 686 KB)
- COS-12/1/2026-eoffice: Public notice on the use of cosmetics (injectables are not cosmetics) (CDSCO, May 18, 2026), opens in a new tab (PDF, 335 KB)
- CDSCO/FAQ/MD/01/2024, Addendum No. 02: Addendum 02 to the Medical Devices FAQ (CDSCO, July 9, 2025), opens in a new tab (PDF, 318 KB)
- CDSCO/FAQ/MD/01/2024, Addendum No. 03: Addendum 03 to the Medical Devices FAQ (CDSCO, November 3, 2025), opens in a new tab (PDF, 374 KB)
- G.S.R. 515(E): Draft amendment of the Medical Devices Rules, 2017: shorter timelines for manufacturing licences (Ministry of Health and Family Welfare, June 23, 2026), opens in a new tab (PDF, 698 KB)
- IT-11011(11)/16/2026: Disposal or rejection of long-pending applications on the SUGAM portal awaiting a reply (more divisions) (CDSCO, May 4, 2026), opens in a new tab (PDF, 779 KB)
- Cosmetics FAQ (Cosmetics Rules, 2020): Frequently Asked Questions on Registration and Import of Cosmetics into India (CDSCO), opens in a new tab (PDF, 518 KB)
- G.S.R. 293(E): Drugs (Third Amendment) Rules, 2024: Cochin and Thiruvananthapuram airports added to rule 43A (Ministry of Health and Family Welfare, May 28, 2024), opens in a new tab (PDF, 717 KB)
- G.S.R. 561(E): Drugs (Ninth Amendment) Rules, 2026: Navi Mumbai airport added to rule 43A (Ministry of Health and Family Welfare, July 2, 2026), opens in a new tab (PDF, 1.1 MB)
- Import/Misc./39/2018-DC (Pt.-12): Timelines for cargo clearances at port offices of CDSCO (CDSCO, September 10, 2021), opens in a new tab (PDF, 1.1 MB)
- S.O. 3068(E) to S.O. 3083(E): Prohibition of 16 fixed dose combinations under section 26A (Ministry of Health and Family Welfare, June 11, 2026), opens in a new tab (PDF, 1.4 MB)
- DCG(I)/Legal/Misc.-160/2025-DC: Public notice on compounding of offences under the Drugs and Cosmetics (Compounding of Offences) Rules, 2025 (CDSCO, January 1, 2026), opens in a new tab (PDF, 347 KB)
- CDSCO/FAQ/CA/01/2025: FAQs on the Drugs and Cosmetics (Compounding of Offences) Rules, 2025 (CDSCO, January 1, 2026), opens in a new tab (PDF, 368 KB)
- S.O. 3286(E): Start date of the Jan Vishwas (Amendment of Provisions) Act, 2026 for the Drugs and Cosmetics Act, 1940 (Ministry of Health and Family Welfare, June 22, 2026), opens in a new tab (PDF, 1.0 MB)
- DC-DT-15011(11)/144/2025-eoffice: Strict compliance with the Drugs Rules, 1945 for testing of raw materials and finished formulations (CDSCO, October 27, 2026), opens in a new tab (PDF, 830 KB)
- G.S.R. 506(E): Drugs (Seventh Amendment) Rules, 2026: more categories under Schedule H2 (Ministry of Health and Family Welfare, June 22, 2026), opens in a new tab (PDF, 664 KB)
- G.S.R. 509(E): Draft amendment of the Drugs Rules, 1945: prior intimation in place of some Form 11 test licences (Ministry of Health and Family Welfare, June 23, 2026), opens in a new tab (PDF, 1.2 MB)
- G.S.R. 790(E): Draft amendment of the New Drugs and Clinical Trials Rules, 2019: prior intimation for some BA/BE studies beyond export (Ministry of Health and Family Welfare, September 3, 2026), opens in a new tab (PDF, 681 KB)
- COS-13011/4/2026-eoffice: Compliance of imported and manufactured hair color products with the Cosmetics Rules, 2020 and BIS standards (CDSCO, June 10, 2026), opens in a new tab (PDF, 349 KB)